Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 12

recruiting
3 968
countries
28
conditions
2 103

756 trials match your criteria

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AB521

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dapagliflozin

Depression

Recruiting

Testing dehydroepiandrosterone combined with standard antidepressants for patients with treatment-resistant depression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lactose Monohydrate

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:FRUQUINTINIB

Asthma

Recruiting

Testing WIN378 Safety and Effects in Adults with Moderate or Severe Asthma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST TSLP

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Db-1303

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Study of Axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Axatilimab

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.